Cobleigh MA - Search Results

1

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. Vogel C, et al. Among authors: cobleigh ma. Eur J Cancer. 2001 Jan;37 Suppl 1:25-29. Eur J Cancer. 2001. PMID: 11342197

2

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Vogel CL, et al. Among authors: cobleigh ma. J Clin Oncol. 2002 Feb 1;20(3):719-26. doi: 10.1200/JCO.2002.20.3.719. J Clin Oncol. 2002. PMID: 11821453 Clinical Trial.

3

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ; Genentech H0650 study investigators. Vogel C, et al. Among authors: cobleigh ma. Eur J Cancer. 2001 Jan;37 Suppl 1:S25-9. Eur J Cancer. 2001. PMID: 11167088 Review.

4

First-line Herceptin monotherapy in metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. Vogel CL, et al. Among authors: cobleigh ma. Oncology. 2001;61 Suppl 2:37-42. doi: 10.1159/000055400. Oncology. 2001. PMID: 11694786 Review.

5

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Tripathy D, et al. J Clin Oncol. 2004 Mar 15;22(6):1063-70. doi: 10.1200/JCO.2004.06.557. J Clin Oncol. 2004. PMID: 15020607 Clinical Trial.

6

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Cobleigh MA, et al. J Clin Oncol. 1999 Sep;17(9):2639-48. doi: 10.1200/JCO.1999.17.9.2639. J Clin Oncol. 1999. PMID: 10561337 Clinical Trial.

7

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Michiels S, et al. Ann Oncol. 2016 Jun;27(6):1029-1034. doi: 10.1093/annonc/mdw132. Epub 2016 Mar 8. Ann Oncol. 2016. PMID: 26961151 Free article.

8

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Mass RD, et al. Among authors: cobleigh ma. Clin Breast Cancer. 2005 Aug;6(3):240-6. doi: 10.3816/CBC.2005.n.026. Clin Breast Cancer. 2005. PMID: 16137435

9

Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.

Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M. Kaufman PA, et al. Breast Cancer Res Treat. 2021 Jul;188(1):179-190. doi: 10.1007/s10549-021-06103-z. Epub 2021 Feb 28. Breast Cancer Res Treat. 2021. PMID: 33641083

10

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. Cobleigh MA, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24. doi: 10.1053/j.seminoncol.2003.08.013. Semin Oncol. 2003. PMID: 14613032 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters